Search Results

IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announced the publication of a significant research article in the European Society of Medicine Journal. The study investigates the effects of CYP2C9 polymorphisms on the pharmacokinetics (“PK”) of delta-9-tetrahydrocannabinol (“THC”) and its active metabolite in Alzheimer’s disease (“AD”) patients.

HUTCHMED Limited announces that it will host a R&D update in Shanghai, China, and via webcast on Tuesday, July 9, 2024.

Alpha-9 Oncology announced that the first participant has been dosed in the Phase 1 study evaluating 68Ga-A9-3202, a radiodiagnostic targeting melanocortin 1 receptor for the imaging of locally advanced or metastatic melanoma.

Simulations Plus, Inc. today announced the release of GastroPlus® 9.9, the latest version of its flagship physiologically based pharmacokinetics/biopharmaceutics (PBPK/PBBM) modeling and simulation software.

Axena Health, Inc., a medical device company focused on female pelvic health, has closed on an additional $9.4 million in its Series A fundraising.

InspireMD, Inc., developer of the CGuard™ Embolic Prevention Stent System for the prevention of stroke, announced the completion of the full exercise of 12.9 million Series H warrants.

ERS Genomics Limited, the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, announced a non-exclusive CRISPR/Cas9 license agreement.

Alto Neuroscience’s depression treatment failed to beat placebo just nine months after the biotech went public. The stunning failure called to mind Acelyrin, which faced a similar fate last year.